

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	MGC Pharmaceuticals Limited
ABN	30 116 800 269

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Ross Grant Thomas Walker
Date of last notice	12 April 2022

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Ross G T Walker Pty Ltd
Date of change	5 May 2023
No. of securities held prior to change	Ross G T Walker Pty Ltd: 4,970,370 Fully paid ordinary shares 1,050,000 Performance Rights Class B expiring 1 April 2026
Class	Performance Rights Class B expiring 1 April 2026
Number acquired	N/A
Number disposed	1,050,000
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	\$Nil – Lapse of Performance Rights

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

No. of securities held after change	Ross G T Walker Pty Ltd: 4,970,370 Fully paid ordinary shares
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Lapse of Performance Rights

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	
If prior written clearance was provided, on what date was this provided?	

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	MGC Pharmaceuticals Limited
ABN	30 116 800 269

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Stephen Barry Parker
Date of last notice	9 May 2022

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	1. Direct
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	<p>1. <u>Direct</u> Mr Stephen Barry Parker</p> <p>2. <u>Indirect</u> Held through a UK Individual Savings Account ("ISA") Registered Holder is Barclays Bank PLC (Beneficial Owner)</p> <p>Held through a UK Self Invested Personal Pension ("SIPP") Registered Holder is Hargreaves Lansdown Asset Management Limited (Beneficial Owner)</p>
Date of change	5 May 2023
No. of securities held prior to change	<p>1. <u>Direct holding</u> Mr Stephen Barry Parker 600,000 Fully Paid Ordinary Shares 1,400,000 Performance Rights Class B expiring 1 April 2026</p> <p>2. <u>Indirect holding</u> Barclays Bank PLC 282,316 Fully Paid Ordinary Shares</p> <p>Hargreaves Lansdown Asset Management Limited 1,111,111 Fully Paid Ordinary Shares</p>
Class	Performance Rights Class B expiring 1 April 2026
Number acquired	N/A

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Number disposed	1,400,000
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	\$Nil – Lapse of Performance Rights
No. of securities held after change	<ol style="list-style-type: none"> 1. <u>Direct holding</u> Mr Stephen Barry Parker 600,000 Fully Paid Ordinary Shares 2. <u>Indirect holding</u> Barclays Bank PLC 282,316 Fully Paid Ordinary Shares Hargreaves Lansdown Asset Management Limited 1,111,111 Fully Paid Ordinary Shares
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Lapse of Performance Rights

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

If prior written clearance was provided, on what date was this provided?	
---	--

Rule 3.19A.2

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	MGC Pharmaceuticals Limited
ABN	30 116 800 269

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Nativ Segev
Date of last notice	12 April 2022

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct & Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Brighthouse Global Limited (Director and sole shareholder) HSBC Custody Nominees (Australia) Limited (Beneficiary)
Date of change	5 May 2023
No. of securities held prior to change	Direct: 1 Fully Paid Ordinary Share Brighthouse Global Limited: 5,500,000 Fully Paid Ordinary Shares 1,050,000 Performance Rights Class B expiring 1 April 2026 600,000 Performance Rights Class C expiring 30 June 2024 HSBC Custody Nominee (Australia) Limited: 52,500,000 Fully Paid Ordinary Shares
Class	Performance Rights Class B expiring 1 April 2026
Number acquired	N/A
Number disposed	1,050,000
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	\$Nil – Lapse of Performance Rights

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

No. of securities held after change	Direct: 1 Fully Paid Ordinary Share Bright Global Limited: 5,500,000 Fully Paid Ordinary Shares 600,000 Performance Rights Class C expiring 30 June 2024 HSBC Custody Nominee (Australia) Limited: 52,500,000 Fully Paid Ordinary Shares
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Lapse of Performance Rights

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	N/A
If so, was prior written clearance provided to allow the trade to proceed during this period?	
If prior written clearance was provided, on what date was this provided?	

⁺ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	MGC Pharmaceuticals Limited
ABN	30 116 800 269

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Brett Anthony Mitchell
Date of last notice	12 April 2022

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	Brett and Michelle Mitchell <Mitchell Spring Family A/C> Trustee Brett and Michelle Mitchell <Lefthanders Super Fund A/C> Trustee
Date of change	5 May 2023
No. of securities held prior to change	Brett and Michelle Mitchell <Mitchell Spring Family A/C> 22,542,221 Fully Paid Ordinary Shares 1,250,000 Performance Rights 17,500,000 Performance Rights Class B expiring 1 April 2026 Brett and Michelle Mitchell <Lefthanders Super Fund A/C> 8,418,337 Fully Paid Ordinary Shares 1,250,000 Performance Rights 2,400,000 Performance Rights Class C expiring 30 June 2024 YCAGAGF Investments Pty Ltd 1,500,000 Unlisted Options exercisable at \$0.05 expiring 31 August 2023 1,500,000 Unlisted Options exercisable at \$0.06 expiring 31 August 2023 1,500,000 Unlisted Options exercisable at \$0.07 expiring 31 August 2023
Class	Performance Rights Class B expiring 1 April 2026
Number acquired	N/A

+ See chapter 19 for defined terms.

Appendix 3Y Change of Director's Interest Notice

Number disposed	17,500,000
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	\$Nil - Lapse of Performance Rights
No. of securities held after change	<p>Brett and Michelle Mitchell <Mitchell Spring Family A/C> 22,542,221 Fully Paid Ordinary Shares 1,250,000 Performance Rights</p> <p>Brett and Michelle Mitchell <Lefthanders Super Fund A/C> 8,418,337 Fully Paid Ordinary Shares 1,250,000 Performance Rights 2,400,000 Performance Rights Class C expiring 30 June 2024</p> <p>YCAGAGF Investments Pty Ltd 1,500,000 Unlisted Options exercisable at \$0.05 expiring 31 August 2023 1,500,000 Unlisted Options exercisable at \$0.06 expiring 31 August 2023 1,500,000 Unlisted Options exercisable at \$0.07 expiring 31 August 2023</p>
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Lapse of Performance Rights

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	N/A
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

Part 3 – +Closed period

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	
If prior written clearance was provided, on what date was this provided?	

⁺ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	MGC Pharmaceuticals Limited
ABN	30 116 800 269

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Roby Reuven Zomer
Date of last notice	9 May 2022

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Chitta Lu Limited (Director and sole shareholder) & HSBC Custody Nominees (Australia) Limited (Beneficial Owner)
Date of change	5 May 2023
No. of securities held prior to change	Chitta Lu Limited 1 Fully Paid Ordinary Shares 2,500,000 Performance Rights 17,500,000 Performance Rights Class B expiring 1 April 2026 2,400,000 Performance Rights Class C expiring 30 June 2024 HSBC Custody Nominees (Australia) Limited 33,819,672 Fully Paid Ordinary Shares
Class	Performance Rights Class B expiring 1 April 2026
Number acquired	N/A

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Number disposed	17,500,000
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	\$Nil – Lapse of Performance Rights
No. of securities held after change	Chitta Lu Limited 1 Fully Paid Ordinary Shares 2,500,000 Performance Rights 2,400,000 Performance Rights Class C expiring 30 June 2024 HSBC Custody Nominees (Australia) Limited 33,819,672 Fully Paid Ordinary Shares
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Lapse of Performance Rights

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	N/A
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	

⁺ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

If prior written clearance was provided, on what date was this provided?	
---	--

+ See chapter 19 for defined terms.